Home/NorthStrive Biotherapeutics/Deniel Mero

DM

Deniel Mero

Co-Founder

NorthStrive Biotherapeutics

Therapeutic Areas

Obesity Metabolic Disorders

NorthStrive Biotherapeutics Pipeline

Drug	Indication	Phase
EL-22	Preservation of lean muscle mass in patients on GLP-1 therapy for obesity	Phase 1

Leadership Team at NorthStrive Biotherapeutics

Graydon Bensler, CFA

Chief Executive Officer & Chief Financial Officer

View full NorthStrive Biotherapeutics profile